- Home
- RGLS
as 07-26-2024 4:00pm EST
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 132.2M | IPO Year: | 2012 |
| Target Price: | $11.00 | AVG Volume (30 days): | 881.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.08 - $3.79 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Regulus Therapeutics Inc. (RGLS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| CALSADA CRISPINA | RGLS | Chief Financial Officer | Jan 18 '24 | Sell | $1.19 | 5,468 | $6,510.20 | 5,782 | SEC Form 4 |
| Aker Christopher Ray | RGLS | Sr. VP & General Counsel | Jan 18 '24 | Sell | $1.19 | 5,468 | $6,510.20 | 10,056 | SEC Form 4 |
| Hagan Joseph P | RGLS | Chief Executive Officer | Jan 18 '24 | Sell | $1.19 | 14,580 | $17,358.95 | 57,112 | SEC Form 4 |
Latest Regulus Therapeutics Inc. News
RGLS Breaking Stock News: Dive into RGLS Ticker-Specific Updates for Smart Investing
PR Newswire
18 days ago
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
MT Newswires
a month ago
Canaccord Genuity Raises Price Target on Regulus Therapeutics to $28 From $11, Maintains Buy Rating
MT Newswires
a month ago
HC Wainwright Raises Regulus Therapeutics Price Target to $10 From $9, Maintains Buy Rating
MT Newswires
a month ago
Regulus Therapeutics Says Potential Kidney Disease Drug Well-Tolerated in Phase 1b Study
MT Newswires
a month ago
Top Premarket Gainers
PR Newswire
a month ago
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Simply Wall St.
a month ago
Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
PR Newswire
2 months ago
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
Compare RGLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGLS Regulus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.